United States Department of State



Washington, D.C. 20520

UNCLASSIFIED 6/11/2021

MEMO FOR DONALD WRIGHT, U.S. AMBASSADOR TO TANZANIA

SUBJECT: PEPFAR Tanzania Country Operational Plan 2021 Approval

This memo represents the successful completion of the PEPFAR Tanzania Country Operational Plan (COP) 2021 planning, development and submission. PEPFAR Tanzania, together with the partner government, civil society and multilateral partners, has planned and submitted a COP 2021 in alignment with the directives from the COP 2021 planning letter, data-driven decisions made during the in-country retreat, and agreements made during the planning meeting.

This memo serves as the approval for the PEPFAR Tanzania Country Operational Plan (COP) 2021 with a total approved budget of \$468,821,930, including all initiatives and applied pipeline, to achieve the targets and outcomes as listed in this memo and all appendices. Total budget is reflective of the following programming:

	New Funding (All Accounts)	Pipeline	Total Budget FY 2022 Implementation
TOTAL	422,606,585	46,215,345	468,821,930
Bilateral	422,106,585	46,215,345	468,321,930
Central	500,000		500,000

The total FY 2022 outlay for COP 2021 implementation shall not exceed the total approved COP 2021 budget of \$468,321,930 without additional written approval. Any prior year funds that are not included within this COP 2021 budget and documented within this memo, its appendices and official PEPFAR data systems are not to be made available for execution and outlay during FY 2022 without additional written approval. The new FY 2021 funding and prior year funds approved within this memo as a part of the total COP 2021 budget are allocated to achieve specific results, outcomes and impacts as approved. All requested Operational Plan Updates and shifting of funds – either between mechanisms and partners, or to add additional funding to mechanisms and partners for execution in FY 2022– must be submitted to and approved by S/GAC.

Approved funding will be made available to agencies for allocation to country platform to implement COP 2021 programming and priorities as outlined below and in the appendix. **Background**

This approval is based upon: the discussions that occurred between the country team, agency headquarters, S/GAC, local and global stakeholders and partners during the April 27-28, 2021 virtual planning meetings and participants in the virtual approval meeting; the final COP 2021

submission, including all data submitted via official PEPFAR systems or within supplemental documents.

Program Summary

Funding and targets for Tanzania's Country Operational Plan (COP) 2021 will support PEPFAR Tanzania's vision in partnership with the Government of Tanzania (GOT) to work towards epidemic control by scaling up targeted testing strategies to efficiently identify people living with HIV (PLHIV); ensuring all newly diagnosed PLHIV are immediately linked to treatment; and ensuring all PLHIV are retained on treatment and remain virally suppressed. Building on the gains from COP 2019 and COP 2020 implementation, COP 2021 will work towards the attainment of epidemic control (95-95-95 goals) across all ages and sexes through the end of FY2022. Accordingly, the program for COP 2021 will work toward the goal of maintaining 1,565,858 PLHIV across the country on life-saving treatment, enrolling 139,796 PLHIV newly on treatment, and ensuring viral load suppression in 1,477,993 patients by the end of FY 2022.

The PEPFAR Tanzania strategy for programming to be implemented in FY 2022 will be grounded in the commitment and the strategic decision to utilize data-driven processes to identify program gaps and measure progress against closing those gaps. Essential to this process will be the conduction of the second Tanzania HIV/AIDS Impact Survey (THIS) to provide updated assessments on programmatic progress and data that will inform PEPFAR priorities. Continuous engagement of the GOT, stakeholders and implementing partners in the development and implementation of effective strategies to rapidly respond to programmatic shifts will also be critical. Although a large majority of programmatic successes in COP 18 & 19 have been maintained through the end of FY 2020, the impact of the COVID-19 pandemic on the PEPFAR Tanzania program has been substantial. Looking ahead to COP21, PEPFAR Tanzania will focus on regaining program momentum towards the achievement of UNAIDS 95-95-95 goals by bringing key interventions to scale, while ensuring the safety of clients, healthcare workers, and implementing partner staff. Success will rely upon having systems and policies in place to support the implementation of programmatic best practices. The specific focus in COP 21 will include: (1) scale-up of HIV case finding strategies, especially for hard to reach populations, with an enhanced effort to provide high quality, non-coercive, and confidential index testing; (2) rapid acceleration of ART enrollment, ensuring optimization of ARV regimens for pediatric and adult clients, including the use of differentiated service delivery models; (3) strengthened program retention with the goal of increasing community viral load suppression and morbidity and mortality reduction; (4) integration of recency surveillance into routine HIV testing services (HTS); (5) optimization of laboratory infrastructure to support timely and comprehensive viral load testing services; and (6) strengthened HIV combination prevention to decrease the number of incident HIV infections in Tanzania. All efforts will be complemented by efforts to address widespread stigma and discrimination that leads to fear of testing and reduction in service quality for people living with HIV.

In FY 2022, PEPFAR funds for Tanzania will be heavily invested in optimizing and bringing to scale key strategies to find and link the most vulnerable Tanzanians to prevention and lifesaving treatment services. Continued engagement of the Key and Vulnerable Population (KVP) forum will ensure that lessons learned from the KP investment fund (KPIF) will be integrated and

effectively implemented at the community level. VMMC services will capitalize on a successful COP 19/20 pivot to focus on older men with an enhanced focus on innovative demand creation approaches to engage this population. Combination prevention strategies such as DREAMS will expand its reach to enroll the most at-risk adolescent girls and young women (AGYW), including pregnant and breastfeeding AGYW, with enhanced economic strengthening activities and mentorship in all councils. During the May COP 2021 meetings, the GOT approved the National PrEP Framework and committed to commence with the immediate scale-up of preexposure prophylaxis (PrEP) for vulnerable and key populations beginning in June 2021. In COP 2021, PEPFAR/Tanzania will reach 50,000+ new clients, including AGYW, serodiscordant couples and other at risk populations with this critical HIV prevention intervention. PEPFAR Tanzania will also rapidly accelerate nationwide 6-multi-month dispensing (6MMD) and the timely transition to pediatric DTG-10. Treatment literacy at the facility and community level will be scaled to strengthen treatment linkage and minimize patient loss. Community-ART enrollment and refills will continue for key and vulnerable populations with an expansion to the general population. PEPFAR Tanzania will also collaborate with the GOT to conduct an in-depth review of the national laboratory infrastructure to develop a plan to optimize the laboratory network in order to maximize EID and viral load testing efficiencies and minimize supply chain disruptions. Continued investments in the OVC program will be leveraged to enhance pediatric case finding and treatment support efforts to address current gaps in the pediatric cascade. To this end, the PEPFAR Tanzania team will continuously review program data from the OVC program in COP 20/21 to ensure that the program is geographically aligned with HIV burden, reaching the most vulnerable children and families with comprehensive services. Finally, above site investments will focus on supporting all of these priorities through the development of systems for rapid access to and use of high-quality data to inform strategic priorities; supply chain strengthening to deliver life-saving commodities; building health worker capacity; laboratory investments to ensure quality and timely viral testing and monitoring; and institutional strengthening that will continue steps towards sustainability.

During COP 2021, PEPFAR Tanzania will continue to invest in the highest HIV burden districts covering all PLHIV. In COP 2020 PEPFAR expanded to cover 197 councils in order to achieve the 95-95-95 goals. With the purpose of addressing the geographic shift in PLHIV distributions in Tanzania that occurred as a response to COVID-19 migrations, in COP 2021 PEPFAR Tanzania will continue to prioritize these 197 councils with an enhanced focus on using current data to ensure that investments remain geographically aligned with high HIV burden areas (i.e. the Lake Zone, the Southern Highlands, and Dar Es Salaam). Broad gaps in testing coverage across age and sex bands will be addressed through evidence-based implementation of enhanced index testing, optimized provider-initiated testing and counseling (PITC), HIV self-testing scaleup and client centered targeted community testing. All retention activities initiated in COP 2020; such as strengthened OVC clinical linkages to improve the pediatric cascade, Undetectable equals Untransmittable (U=U) messaging, expanded linkage case management (LCM) for new clients, and the "Operation Triple Zero" strategy to enhance retention and viral load suppression among adolescents and young persons; will continue in COP 2021 with a focus on the real-time assessment of any gaps at the facility level for quality improvement. PEPFAR Tanzania will also support the GoT to optimize the laboratory infrastructure and systems to enhance efficiencies and support sustainability efforts. In addition, the DREAMS program for adolescent girls and young women will build upon successes from its expansion to 11 councils in COP 2020 by

formalizing/standardizing the mentorship program, focusing on increased recruitment of pregnant and breastfeeding AGYW into DREAMS, expanding economic strengthening activities into the remaining 8 councils, and employing more DREAMS Ambassadors at the regional and district level. Pediatric anti-retroviral therapy (ART) coverage and formulations will be optimized in COP 2021 through GoT supported introduction and rapid scale-up of DTG-10 across Tanzania. The VMMC program will perform >432,000 circumcisions in men ≥ 15yrs and over 300,000 WLHIV aged 25-49yrs will be screened for cervical cancer in COP 21, with prevention efforts focused on demand creation, service integration, and quality assured practices for both of these programs. Key population social networks and community platforms will be leveraged for distribution of HIV self-test kits, where PEPFAR Tanzania aims to target 50% of the KP testing gap with self-testing services in COP 2021. In addition, PEPFAR/ Tanzania will bring to scale the Peer Navigator Linkage Case Management Model for key populations receiving testing services. For clients newly identified positive, key Implementing Partner strategies include initiation on a Community 30- day ART starter pack and linkage of HIV positive clients with peer navigators at each testing point to facilitate linkage to treatment, with up to 6 month follow up for all clients newly initiated on ART. For clients with a negative HIV status, KPs will be provided with, or referred for, other prevention and clinical services. PEPFAR-supported community implementing partners will scale-up community ART refills by offering multi-month dispensing through mobile clinics. The synergistic impact of data-driven facility and community-based HIV testing, expanded LCM for high-risk and vulnerable groups, differentiated service delivery models, optimized treatment regimens, and strengthened client centered approaches will accelerate Tanzania's efforts to achieve epidemic control in COP 2021.

American Rescue Plan Act of 2021 Summary Description

This memo approves \$20,500,000 in ARPA funds in the Economic Support Fund (ESF) account to be implemented for activities during COP 2020 and COP 2021. Of the total \$20,500,000 in ARPA funds, \$18,321,930 is expected to be implemented in COP 2021; these funds are included in the other tables found in this memo. The remaining \$2,178,070 is expected to be implemented in COP 2020. The table below shows the estimated breakout of outlays in COP 2021 versus COP 2020 by implementing agency and operational division.

Agency/OPDIV	ARPA Funds Programmed in COP21 FAST for COP21 Outlay	ARPA Funds To be Added to COP20 for COP20 Outlay	TOTAL ARPA Funds
TOTAL	\$18,321,930	\$2,178,070	\$20,500,000
DOD	\$3,288,559	\$0	\$3,288,559
HHS/CDC	\$9,963,005	\$0	\$9,963,005
HHS/HRSA	\$0	\$0	\$0

PC	\$0	\$0	\$0
USAID	\$5,070,366	\$2,178,070	\$7,248,436
USAID/WCF	\$0	\$0	\$0

Any ARPA funds not outlayed in COP 2020 will be allowed to outlay in COP 2021, and this will be accounted for in the End of Fiscal Year exercise in the Fall of 2021. The entire ARPA amount must be obligated by September 30, 2022 and should, except in extraordinary circumstances, be outlayed during COP 2021.

These ARPA funds are being provided specifically to address the intersection of HIV and COVID to prevent, prepare for, and respond to coronavirus (including prevention of COVID-19 infection, illness, and death among PEPFAR beneficiaries and staff); and Mitigate COVID-19 impact on PEPFAR programs and beneficiaries and support PEPFAR program recovery from the impacts of coronavirus. Over the course of COP 2020 and COP 2021, the ARPA funds will support: infection prevention and control (IPC) measures to protect health facility staff at PEPFAR supported sites, laboratory support for COVID-19 genetic sequencing, support for vaccine rollout planning and dissemination to health care workers, mitigation of losses in pediatric HIV program performance due to the pandemic, COVID-19 case management, the expansion of community antiretroviral therapy (ART) distribution, and support to train a cadre of community health workers to support activities that reach orphans and vulnerable children. Funds will also be used to support Tanzania's National Oxygen Scale-up Plan and to enhance laboratory surveillance at PEPFAR-supported facilities to guide decisions to scale-up or down PEPFAR services in the face of outbreaks or new strains. This plan has been developed based on priorities outlined in Tanzania's National COVID-19 Response Plan and is designed to align with and be complementary to Tanzania's Global Fund COVID-19 Response Mechanism (C19RM) application.

Faith and Communities Initiative (FCI)

The implementation of the FCI has been significantly delayed by COVID. Accordingly, any remaining FCI funds at the end of COP20 will be allowed to carry over into COP21. After exact amounts of carryover are determined during the End of Fiscal Year process in fall of 2021, COP 21 envelopes will be updated to account for this carryover.

Recency

The implementation of the Recency activities has also been significantly delayed by COVID. Accordingly, any remaining Recency funds at the end of COP20 will be allowed to carry over into COP21. After exact amounts of carryover are determined during the End of Fiscal Year process in fall of 2021, COP 21 envelopes will be updated to account for this carryover.

Funding Summary

All COP 2021 funding summarized in the charts below is approved at the agency and account levels as indicated. <u>Funds are to be utilized to achieve the targets and outcomes and to fund implementing partners and Management and Operations costs (U.S. Government Costs of Doing Business) as documented in all PEPFAR systems and summarized in the appendix.</u>

		of which, Bilateral										
			New Funding								Budget	
	Total				FY 2021			FY 2020	FY 2019	Applied Pipeline	(Bilateral + Central)	
		Total	Total	GHP-State	GHP-USAID	GAP	ESF	GHP-State	GHP-State			
TOTAL	468,321,930	422,106,585	422,106,585	366,165,905	35,000,000	2,618,750	18,321,930		-	46,215,345	468,821,930	
DOD Total	52,401,900	50,123,390	50,123,390	46,834,831	-	-	3,288,559		-	2,278,510	52,401,900	
DOD	52,401,900	50,123,390	50,123,390	46,834,831	-	-	3,288,559	-	-	2,278,510	52,401,900	
HHS Total	169,451,028	169,451,028	169,451,028	156,869,273	-	2,618,750	9,963,005	-	-	-	169,451,028	
HHS/CDC	169,451,028	169,451,028	169,451,028	156,869,273	-	2,618,750	9,963,005	-	-	-	169,451,028	
PC Total	2,823,746	-	-	-	-	-	-		-	2,823,746	2,823,746	
PC	2,823,746	-	-	-	-	-	-	-	-	2,823,746	2,823,746	
STATE Total	1,046,780	475,927	475,927	475,927	-	-	-		-	570,853	1,046,780	
State	240,052	240,052	240,052	240,052	-	-	-	-	-	-	240,052	
State/AF	806,728	235,875	235,875	235,875	-	-	-	-	-	570,853	806,728	
USAID Total	242,598,476	202,056,240	202,056,240	161,985,874	35,000,000	-	5,070,366		-	40,542,236	243,098,476	
USAID, non-WCF	145,413,645	117,457,778	117,457,778	77,387,412	35,000,000	-	5,070,366	-	-	27,955,867	145,413,645	
USAID/WCF	97,184,831	84,598,462	84,598,462	84,598,462	-	-	-	-	-	12,586,369	97,684,831	

^{1/}Applied Pipeline refers to funding allocated in prior years, approved for implementation in FY 2022.

2/Economic Support Fund (ESF) funding is authorized in the American Rescue Plan Act of 2021 and must be used for a combined HIV and COVID purpose.

		of which, Central											
					New F	unding					Budget		
	Total				FY 2021			FY 2020	FY 2019	Applied Pipeline	(Bilateral + Central)		
		Total	Total	GHP-State	GHP-USAID	GAP	ESF	GHP-State	GHP-State				
TOTAL	500,000	500,000	500,000	-	500,000	-	-	-	-	-	468,821,930		
DOD Total	-			-		-	-	-	-	-	52,401,900		
DOD	-	-	-	-	-	-	-	-	-	-	52,401,900		
HHS Total	-			-		-	-	-	-	-	169,451,028		
HHS/CDC	-	-	-	-	-	-	-	-	-	-	169,451,028		
PC Total	-		-	-	-	-	-	-	-	-	2,823,746		
PC	-	-	-	-	-	-	-	-	-	-	2,823,746		
STATE Total	-		-				-	-	-	-	1,046,780		
State	-	-	-	-	-	-	-	-	-	-	240,052		
State/AF	-	-	-	-	-	-	-	-	-	-	806,728		
USAID Total	500,000	500,000	500,000	-	500,000	-	-	-	-	-	243,098,476		
USAID, non-WCF	-	-	-	-	-	-	-	-	-	-	145,413,645		
USAID/WCF	500,000	500,000	500,000	-	500,000	-	-	-	-	-	97,684,831		

^{1/}Applied Pipeline refers to funding allocated in prior years, approved for implementation in FY 2022.

^{2/}Economic Support Fund (ESF) funding is authorized in the American Rescue Plan Act of 2021 and must be used for a combined HIV and COVID purpose.

GHP-State Funds: Upon the clearance of a FY 2021 PEPFAR GHP-State Congressional Notification (CN), funds will be made available for transfer to agency HQs as indicated in the above chart. Funds are made available for outlay in FY 2022 at approved COP 2021 partner budget levels to achieve FY 2022 targets and outcomes as documented in official PEPFAR systems and summarized in the approval memo's appendix. Upon receipt from S/GAC, agency headquarters will move the funds to the country platform via each agency's internal process.

CDC GAP Funds: With the receipt of this signed memo, CDC is approved to use CDC GAP funds, as indicated in the above funding chart. Funds are to be made available for outlay in FY 2022 at approved COP 2021 partner budget levels to achieve FY 2022 targets and outcomes as documented in official PEPFAR systems and summarized in the approval memo's appendix. With this approval, CDC GAP funding may be made available to country teams per CDC internal processes and following agency requirements.

GHP-USAID Funds: With the receipt of this signed memo, USAID is approved to use GHP-USAID funds, as indicated in the above funding chart. Funds are to be made available for outlay in FY 2022 at approved COP 2021 partner budget levels to achieve FY 2022 targets and outcomes as documented in official PEPFAR systems and summarized in the approval memo's appendix. With this approval, GHP-USAID funding may be made available to country teams per USAID internal processes and following agency requirements.

ARP ESF Funds: ESF funds must have both an HIV and COVID related purpose as laid out in relevant S/GAC guidance. Upon the clearance of a FY 2021 PEPFAR ESF Congressional Notification (CN), funds will be made available for transfer to agency HQs as indicated in the above chart. Funds are made available for outlay in FY 2022 at approved COP 2021 partner budget levels to achieve FY 2022 targets and outcomes as documented in official PEPFAR systems and summarized in the approval memo's appendix. Upon receipt, agency headquarters will move the funds to the country platform via each agency's internal process.

Applied Pipeline Funds: With the receipt of this signed memo, respective agencies are approved to use applied pipeline funds as indicated in the above funding chart. Funds are to be made available for outlay in FY 2022 at approved COP 2021 partner budget levels to achieve FY 2022 targets and outcomes as documented in official PEPFAR systems and summarized in the approval memo's appendix. Additional or remaining pipeline from previous year's activities that are not currently captured in the COP 2021 total budget level and documented within COP 2021 partner budgets are not to be executed or outlayed without written approval from S/GAC.

Earmarks: The OU has planned for programming for FY 2021, FY 2020, and/or FY 2019 GHP-State funding that it considered to meet a number of earmarks, as indicated in the table below. The amounts programmed during COP may exceed the original controls assigned to the OU. Upon approval of this memo, the amounts below will become the new earmark controls for the OU/Agency. Any changes to the amount of funding programmed for earmark-eligible activities must be approved via an OPU.

	COP21 Funding Level							
Earmarks	TOTAL	FY 2021	FY 2020	FY 2019				
Care & Treatment	260,565,673	260,565,673	=	-				
Orphans and Vulnerable Children	37,000,812	37,000,812	=	=				
Preventing and Responding to Gender-based Violence	10,340,965	10,340,965	-	-				
Water	2,160,611	2,160,611	Ĭ.	=				

^{*} Only GHP-State and GHP-USAID will count towards the Care and Treatment and OVC earmarks

^{**} Only GHP-State will count towards the GBV and Water earmarks

	COP21 Funding Level							
AB/Y Earmark	TOTAL	FY 2021	FY 2020	FY 2019	Applied Pipeline			
TOTAL Prevention Programming	26,465,659	26,465,659	-	-	-			
Of which, AB/Y	16,812,069	16,812,069	-	-	-			
% AB/Y of TOTAL Sexual Prevention Programming	63.5%	63.5%	N/A	N/A	N/A			

^{1/}Applied Pipeline refers to funding allocated in prior years, approved for implementation in FY 2022.

AB/Y Earmark Budget Justification

AB/Y Requirement Met.

Initiatives by Agency

	Total Central	Total Bilateral	Total Central - New	Total Bilateral -	Total COP21
	Applied Pipeline	Applied Pipeline	Funding	New Funding	Budget
TOTAL	-	46,215,345	500,000	422,106,585	468,821,930
of which, Cervical Cancer	-	-	-	3,531,000	3,531,000
of which, Community-Led Monitoring	-	108,864	-	916,136	1,025,000
of which, Condoms (GHP-USAID Central Funding) (Central)	-	-	500,000	-	500,000
of which, Core Program	-	43,473,238	-	353,620,745	397,093,983
of which, DREAMS	-	-	-	25,000,000	25,000,000
of which, Surveillance and Public					
Health Response	-	-	-	18,321,930	18,321,930
of which, VMMC	-	2,633,243	-	20,716,774	23,350,017
DOD Total	-	2,278,510	-	50,123,390	52,401,900
of which, Cervical Cancer	-	-	-	805,682	805,682
of which, Community-Led Monitoring	-	-	-	275,000	275,000
of which, Core Program	-	2,027,220	-	36,138,540	38,165,760
of which, DREAMS	-	-	-	3,647,000	3,647,000
of which, Surveillance and Public				2 200 550	2 222 552
Health Response	-	-	-	3,288,559	3,288,559
of which, VMMC	-	251,290	-	5,968,609	6,219,899
HHS Total	-	-	-	169,451,028	169,451,028
of which, Cervical Cancer	-	-	-	1,600,965	1,600,965
of which, Core Program	-	-	-	145,218,048	145,218,048
of which, DREAMS	-	-	-	3,389,000	3,389,000
of which, Surveillance and Public				0.063.005	0.062.005
Health Response	-	-	-	9,963,005	9,963,005
of which, VMMC	-	-	-	9,280,010	9,280,010
PC Total	-	2,823,746	-	-	2,823,746
of which, Core Program	-	2,823,746	-	-	2,823,746
STATE Total	-	570,853	-	475,927	1,046,780
of which, Community-Led Monitoring	-	108,864	-	191,136	300,000
of which, Core Program	-	461,989	-	284,791	746,780
USAID Total	-	40,542,236	500,000	202,056,240	243,098,476
of which, Cervical Cancer	-	-	-	1,124,353	1,124,353
of which, Community-Led Monitoring	-	-	-	450,000	450,000
of which, Condoms (GHP-USAID			500,000		500,000
Central Funding) (Central)			500,000	-	500,000
of which, Core Program	-	38,160,283	-	171,979,366	210,139,649
of which, DREAMS	-	-	-	17,964,000	17,964,000
of which, Surveillance and Public Health Response	-	-	-	5,070,366	5,070,366
of which, VMMC	_	2,381,953	_	5,468,155	7,850,108
-,	İ	2,001,000	1	5,100,100	.,030,100

FY 2022 Target Summary

FY 2021 funds are released and COP 2021 applied pipeline is approved to achieve the following results in FY 2022.

Indicator	results in F	Y 2022.							
HTS INDEX 155	Indicator	Age	Attained	Scale-Up:		Sustained			Total
HTS INDEX 159	HTS INDEX	∠1 5	5 864			9 199			67 683
HTS_INDEX HTS_INDEX HTS_INDEX HTS_IST			-						
HTS_TST				· · · · · · · · · · · · · · · · · · ·					
HTS_TST									-
HTS_TST_POS									
HTS_TST_POS									
HTS_TST_POS									
HTS_TST_POS Total 18,88 99,292 - 27,910 - 567 146,552 TX_NEW									
IV. NEW				· · · · · · · · · · · · · · · · · · ·					
TX_NEW									
TX_UREW									
TX_CURR				· · · · · · · · · · · · · · · · · · ·	-				
TX_CURR					-				
TX_CURR Total 199,248 1,057,982 - 282,150 - 26,478 1,565,858 TX_PVIS - 15 - 15 - 17,698 TX_PVIS - 15+ 179,205 - 945,222 - 251,108 - 24,760 - 1,400,295 TX_PVIS - 15+ 179,205 - 945,222 - 251,108 - 24,760 - 1,400,295 TX_PVIS - 10tal - 188,049 - 988,593 - 265,838 - 25,513 - 1,477,993 - 20,419 - 349 - 570,783 - 329,654 - 349 - 570,783 - 329,654 - 349 - 570,783 - 329,654 - 349 - 570,783 - 329,654 - 349 - 570,783 - 349 - 570,783 - 349 - 570,783 - 349 - 570,783 - 349 - 724,485 - 0VC_SERV - 10tal - 161,973 - 533,533 - 28,630 - 349 - 724,485 - 0VC_HIVSTAT - 10tal - 61,562 - 255,958 - 20,419 - 348 - 349 - 349 - 349 - 348 - 349 - 349 - 349 - 349 - 349 - 348 - 349 - 349 - 349 - 349 - 349 - 348 - 349 - 349 - 349 - 349 - 349 - 348 - 349 - 349 - 349 - 349 - 349 - 349 - 348 - 349 - 349 - 348 - 349 - 349 - 349 - 348 - 349 - 349 - 349 - 349 - 349 - 348 - 349 - 349 - 349 - 349 - 349 - 348 - 349 - 349 - 349 - 349 - 349 - 348 - 349 - 349 - 349 - 349 - 348 - 349 - 349 - 349 - 349 - 348 - 349 - 349 - 349 - 348 - 349 - 349 - 349 - 348 - 349 - 349 - 349 - 348 - 349 - 349 - 349 - 348 - 349 - 349 - 349 - 349 - 349 - 349 - 349 - 349 - 349 - 349 - 349 - 349 - 349 - 349 - 349 - 348 - 348 - 349 - 349 - 348 - 349 - 349 - 348 - 349 - 349 - 348 - 349 - 349 - 348 - 349 - 349 - 348 - 349 - 349 - 348 - 349 - 349 - 348 - 349 - 349 - 349 - 348 - 349 - 349 - 349 - 348 - 349								-	
TX_PVIS				·					
TX_PVLS									
TX_PVLS					-				_
CKCA_SCRN Total 44,209 222,556 - 56,880 - 6,009 329,654 OVC_SERV 18 130,276 419,739 - 20,419 - 349 570,783 OVC_SERV 184 31,697 113,794 - 8,211 153,702 OVC_SERV Total 161,973 533,533 - 28,630 - 349 724,485 OVC_HIVSTAT Total 61,562 255,958 - 20,419 - 349 338,288 PMTCT_STAT 15+ 127,751 455,231 - 10,992 - 180 8,572 PMTCT_STAT 15+ 127,751 455,231 - 120,356 - 13,591 716,929 PMTCT_STAT 70t 128,538 461,744 121,448 - 13,771 725,501 PMTCT_STAT POS 15+ 7,356 18,743 - 3,921 - 719 30,739 PMTCT_STAT POS 15+ 7,356 18,743 - 3,921 - 719 30,739 PMTCT_ART 15+ 7,332 18,713 - 3,919					-				
OVC SERV <18					-		•		
OVC_SERV 18+ 31,697 113,794 - 8,211 - - 153,702 OVC_SERV Total 161,973 533,533 - 28,630 - 349 724,485 PMTCT_STAT 15 787 6,513 - 1,092 - 180 8,572 PMTCT_STAT 15+ 127,751 455,231 - 10,023 - 13,591 716,929 PMTCT_STAT Total 128,538 461,744 - 121,448 - 13,771 725,501 PMTCT_STAT_POS 15 56 94 - 9 - - 159 PMTCT_STAT_POS 15- 7,356 18,743 - 3,921 - 719 30,789 PMTCT_ART 15+ 7,332 18,713 - 3,930 - 718 30,682 PMTCT_ART 154 7,332 18,713 - 3,919 - 718 30,682 PMTCT_ART			1						
OVC_SERV Total 161,973 533,533 - 28,630 - 349 724,485 OVC_HINSTAT Total 61,562 255,958 - 20,419 - 349 338,288 PMTCT_STAT 155 787 6,513 - 1,092 - 180 8,572 PMTCT_STAT 15+ 127,751 455,231 - 120,356 - 13,591 716,929 PMTCT_STAT_POS 115 56 94 - 99 - 159 PMTCT_STAT_POS 15+ 7,356 18,743 - 3,921 - 719 30,739 PMTCT_STAT_POS 15+ 7,356 18,743 - 3,921 - 719 30,739 PMTCT_ART 15+ 7,332 18,713 - 3,930 - 719 30,898 PMTCT_ART 15+ 7,332 18,713 - 3,919 - 718 30,682 PMTCT_EID Total 7,042 17,898 18,805 - 3,928 - 718 30,839 PMTCT_EID Total 7,042 17,898 - 3,735 - 683 29,354 <td></td> <td></td> <td></td> <td></td> <td>-</td> <td></td> <td>-</td> <td>349</td> <td></td>					-		-	349	
OVC_HIVSTAT Total 61,562 255,958 - 20,419 - 349 338,288 PMITCT_STAT 415 787 6,513 - 1,092 - 180 8,572 PMITCT_STAT 15+ 127,751 455,231 - 1,092 - 13,591 716,929 PMITCT_STAT Total 128,538 461,744 - 121,448 - 13,771 725,501 PMITCT_STAT_POS 415 56 94 - 9 - - 159 PMITCT_STAT_POS 15+ 7,356 18,743 - 3,930 - 719 30,879 PMITCT_ART 415 56 92 9 - - 157 PMITCT_ART 15+ 7,332 18,713 - 3,930 - 718 30,682 PMITCT_ART 15+ 7,332 18,713 - 3,935 - 718 30,682 PMITCT_STAT Total <td< td=""><td></td><td></td><td></td><td></td><td>-</td><td></td><td>-</td><td>-</td><td></td></td<>					-		-	-	
PMTCT_STAT <15		Total			-		-		
PMTCT_STAT 15+ 127,751 455,231 - 120,356 - 13,591 716,929 PMTCT_STAT Total 128,538 461,744 - 121,448 - 13,771 725,501 PMTCT_STAT_POS 15+ 7,356 18,743 - 3,921 - 719 30,739 PMTCT_STAT_POS 15+ 7,356 18,743 - 3,921 - 719 30,739 PMTCT_STAT_POS 705 7412 18,837 - 3,930 - 719 30,898 PMTCT_ART 415 56 92 9 - - 157 718 30,682 PMTCT_ART 15+ 7,332 18,713 - 3,919 - 718 30,682 PMTCT_ART 705 7,388 18,805 - 3,928 - 718 30,839 PMTCT_EID Total 7,042 17,898 - 3,735 - 683 29,358 PP_PREV 415 - 1,768 - 162 - - 1,930 PP_PREV 15+ 88,355 422,824 - 17,039 - 4,602 530,899 PP_PREV Total 88,355 422,824 - 17,039 - 4,602 530,899 PP_PREV Total 17,721 130,511 - 26,919 - - 175,151 FM_PMAT Total 598 5,257 - 123 - - 5,978 FMMC_CIRC Total 26,480 312,358 - 89,191 - 4,583 432,612 HTS_SELF 415 - - - - 19 19 19 HTS_SELF 515 102,112 634,368 - 205,616 - 1,181 943,277 FMEP_UREV Total 5,882 36,300 - 10,239 - 451 52,872 FMEP_UREV Total 5,882 36,300 - 10,239 - 451 52,872 FMEP_UREV Total 6,152 39,796 - 11,561 - 451 57,960 TB_STAT 515 57 347 - 1,463 - - 40,508 TB_STAT 515 5,033 30,731 - 7,264 - - 43,028 TB_STAT Total 5,271 32,053 - 7,312 - 44,636 TB_ART Total 1,748 9,224 - 1,463 - - 40,508 TB_ART Total 1,748 9,224 - 1,463 - - 1,209 380,241 TB_PREV 15+ 45,182 230,120 - 64,160 - 2,025 342,087 TB_PREV Total 48,926 258,615 - 69,991 - 2,709 380,241 TX_TB 415 45,182 230,120 - 64,160 - 2,025 342,087 TB_PREV Total 48,926 258,615 - 69,991 - 2,709 380,241 TX_TB 515 12,225 81,778 - 19,555 - 803 114,561 TX_TB 515	OVC_HIVSTAT	Total	61,562	255,958	-	20,419			338,288
PMTCT_STAT Total 128,538 461,744 - 121,448 - 13,771 725,501 PMTCT_STAT_POS cls 56 94 - 9 - - 159 PMTCT_STAT_POS cls 7,356 18,743 - 3,921 - 719 30,739 PMTCT_STAT_POS total 7,412 18,837 - 3,930 - 719 30,888 PMTCT_ART cls 56 92 - 9 - - 157 PMTCT_ART 15+ 7,332 18,805 - 3,919 - 718 30,682 PMTCT_ART Total 7,042 17,898 - 3,735 - 683 29,358 PP_PREV cls - 1,662 - - 1,930 PP_PREV 15+ 88,355 422,056 - 16,877 - 4,602 532,820 KP_PREV Total 17,721 130,511	PMTCT_STAT	<15		6,513	-	1,092	-	180	8,572
PMTCT_STAT_POS <15 56 94 - 9 - - 159 PMTCT_STAT_POS 15+ 7,356 18,743 - 3,921 - 719 30,739 PMTCT_STAT_POS Total 7,412 18,837 - 3,930 - 719 30,739 PMTCT_ART <15 56 92 - 9 - - 157 PMTCT_ART 15+ 7,332 18,713 - 3,919 - 718 30,682 PMTCT_ART Total 7,388 18,805 - 3,928 - 718 30,682 PMTCT_ART Total 7,388 18,805 - 3,928 - 718 30,682 PMTCT_ART Total 7,388 18,805 - 3,928 - 718 30,682 PMTCT_ART Total 7,468 - 162 - - 1,930 PMTCT_ART 70tal 26,880	PMTCT_STAT	15+	127,751	455,231	-	120,356	-	13,591	716,929
PMITCT_STAT_POS 15+ 7,356 18,743 - 3,921 - 719 30,739 PMITCT_STAT_POS Total 7,412 18,837 - 3,930 - 719 30,898 PMITCT_ART 15+ 56 92 - 9 - - 157 PMITCT_ART 15+ 7,332 18,713 - 3,919 - 718 30,682 PMITCT_ART Total 7,388 18,805 - 3,928 - 718 30,682 PMITCT_EID Total 7,042 17,898 - 3,735 - 683 29,358 PP_PREV 15+ 88,355 421,056 - 16,877 - 4,602 530,890 PP_PREV Total 88,355 422,824 - 17,039 - 4,602 532,820 KP_PREV Total 15,78 4,22,824 - 17,039 - 4,602 532,820 KP_	PMTCT_STAT	Total	128,538	461,744	-	121,448		13,771	725,501
PMTCT_STAT_POS Total 7,412 18,837 - 3,930 - 719 30,898 PMTCT_ART <15	PMTCT_STAT_POS	<15	56	94	-	9	-	-	159
PMITCT_ART <15 56 92 - 9 - - 157 PMITCT_ART 15+ 7,332 18,713 - 3,919 - 718 30,682 PMTCT_ART Total 7,388 18,805 - 3,928 - 718 30,839 PMTCT_EID Total 7,042 17,898 - 3,735 - 683 29,358 PP_PREV <15 - 1,768 - 162 - - 1,930 PP_PREV 15+ 88,355 421,056 - 16,877 - 4,602 530,890 PP_PREV Total 88,355 422,824 - 17,039 - 4,602 532,820 KP_MAT Total 598 5,257 - 123 - - - 175,151 KP_MAT Total 26,480 312,358 - 89,191 - 4,583 432,612 HTS_SELF 15+	PMTCT_STAT_POS	15+	7,356	18,743	-	3,921	-	719	30,739
PMTCT_ART 15+ 7,332 18,713 - 3,919 - 718 30,682 PMTCT_ART Total 7,388 18,805 - 3,928 - 718 30,839 PMTCT_EID Total 7,042 17,898 - 3,735 - 683 29,358 PP_PREV <15	PMTCT_STAT_POS	Total	7,412	18,837	-	3,930	-	719	30,898
PMTCT_ART Total 7,388 18,805 - 3,928 - 718 30,839 PMTCT_EID Total 7,042 17,898 - 3,735 - 683 29,358 PP_PREV <15 - 1,768 - 162 - - 1,930 PP_PREV 15+ 88,355 421,056 - 16,877 - 4,602 530,890 PP_PREV Total 88,355 422,824 - 17,039 - 4,602 530,890 KP_PREV Total 17,721 130,511 - 26,919 - - 175,151 KP_MAT Total 598 5,257 - 123 - - 5,978 VMMC_CIRC Total 26,480 312,358 - 89,191 - 4,583 432,612 HTS_SELF 15+ 102,112 634,368 - 205,616 - 1,181 943,277 HTS_SELF Total </td <td>PMTCT_ART</td> <td><15</td> <td>56</td> <td>92</td> <td>-</td> <td>9</td> <td>-</td> <td>-</td> <td>157</td>	PMTCT_ART	<15	56	92	-	9	-	-	157
PMTCT_EID Total 7,042 17,898 - 3,735 - 683 29,358 PP_PREV <15	PMTCT_ART	15+	7,332	18,713	-	3,919	-	718	30,682
PP_PREV <15	PMTCT_ART	Total	7,388	18,805	-	3,928	-	718	30,839
PP_PREV 15+ 88,355 421,056 - 16,877 - 4,602 530,890 PP_PREV Total 88,355 422,824 - 17,039 - 4,602 532,820 KP_PREV Total 17,721 130,511 - 26,919 - - 175,151 KP_MAT Total 598 5,257 - 123 - - 5,978 VMMC_CIRC Total 26,480 312,358 - 89,191 - 4,583 432,612 HTS_SELF <15 - - - - 19	PMTCT_EID	Total	7,042	17,898	-	3,735	-	683	29,358
PP_PREV Total 88,355 422,824 - 17,039 - 4,602 532,820 KP_PREV Total 17,721 130,511 - 26,919 - - 175,151 KP_MAT Total 598 5,257 - 123 - - 5,978 VMMC_CIRC Total 26,480 312,358 - 89,191 - 4,583 432,612 HTS_SELF - - - - 19 19 HTS_SELF 15+ 102,112 634,368 - 205,616 - 1,181 943,277 HTS_SELF Total 102,112 634,368 - 205,616 - 1,200 943,296 PrEP_NEW Total 5,882 36,300 - 10,239 - 451 57,960 TB_STAT Total 6,152 39,796 - 11,561 - 451 57,960 TB_STAT 15+ 5,033	PP_PREV	<15	-	1,768	-	162	-	-	1,930
KP_PREV Total 17,721 130,511 - 26,919 - - 175,151 KP_MAT Total 598 5,257 - 123 - - 5,978 VMMC_CIRC Total 26,480 312,358 - 89,191 - 4,583 432,612 HTS_SELF - - - - - 19 19 HTS_SELF 15+ 102,112 634,368 - 205,616 - 1,181 943,277 HTS_SELF Total 102,112 634,368 - 205,616 - 1,200 943,296 PrEP_NEW Total 5,882 36,300 - 10,239 - 451 52,872 PrEP_CURR Total 6,152 39,796 - 11,561 - 451 57,960 TB_STAT 15+ 5,033 30,731 - 7,264 - - 1,608 TB_ART Total 5	PP_PREV	15+	88,355	421,056	-	16,877	-	4,602	530,890
KP_MAT Total 598 5,257 - 123 - - 5,978 VMMC_CIRC Total 26,480 312,358 - 89,191 - 4,583 432,612 HTS_SELF <15 - - - - - 19 19 HTS_SELF 15+ 102,112 634,368 - 205,616 - 1,181 943,277 HTS_SELF Total 102,112 634,368 - 205,616 - 1,200 943,296 PrEP_NEW Total 5,882 36,300 - 10,239 - 451 52,872 PrEP_CURR Total 6,152 39,796 - 11,561 - 451 57,960 TB_STAT 15+ 5,033 30,731 - 7,264 - - 1,608 TB_ART Total 5,271 32,053 - 7,312 - - 405 TB_ART 15+ 1,691 <td>PP_PREV</td> <td>Total</td> <td>88,355</td> <td>422,824</td> <td>-</td> <td>17,039</td> <td>-</td> <td>4,602</td> <td>532,820</td>	PP_PREV	Total	88,355	422,824	-	17,039	-	4,602	532,820
VMMC_CIRC Total 26,480 312,358 - 89,191 - 4,583 432,612 HTS_SELF <15	KP_PREV	Total	17,721	130,511	-	26,919	-	•	175,151
HTS_SELF <15	KP_MAT	Total	598	5,257	-	123	-	-	5,978
HTS_SELF 15+ 102,112 634,368 - 205,616 - 1,181 943,277 HTS_SELF Total 102,112 634,368 - 205,616 - 1,200 943,296 PrEP_NEW Total 5,882 36,300 - 10,239 - 451 52,872 PrEP_CURR Total 6,152 39,796 - 11,561 - 451 57,960 TB_STAT 215 238 1,322 - 48 - - 1,608 TB_STAT 15+ 5,033 30,731 - 7,264 - - 43,028 TB_STAT Total 5,271 32,053 - 7,312 - - 44,636 TB_ART 15+ 1,691 8,877 - 1,462 - - 12,030 TB_PREV 1,548 9,224 - 1,463 - - 12,435 TB_PREV	VMMC_CIRC	Total	26,480	312,358	-	89,191	-	4,583	432,612
HTS_SELF Total 102,112 634,368 - 205,616 - 1,200 943,296 PrEP_NEW Total 5,882 36,300 - 10,239 - 451 52,872 PrEP_CURR Total 6,152 39,796 - 11,561 - 451 57,960 TB_STAT <15	HTS_SELF	<15	1	-	-	-	-	19	19
PrEP_NEW Total 5,882 36,300 - 10,239 - 451 52,872 PrEP_CURR Total 6,152 39,796 - 11,561 - 451 57,960 TB_STAT 238 1,322 - 48 - - 1,608 TB_STAT 15+ 5,033 30,731 - 7,264 - - 43,028 TB_STAT Total 5,271 32,053 - 7,312 - - 44,636 TB_ART 15 57 347 - 1 - - 405 TB_ART 15+ 1,691 8,877 - 1,462 - - 12,030 TB_PREV 1,748 9,224 - 1,463 - - 12,435 TB_PREV 3,744 28,495 - 5,831 - 84 38,154 TB_PREV Total 48,926	HTS_SELF	15+	102,112	634,368	-	205,616	-	1,181	943,277
PrEP_CURR Total 6,152 39,796 - 11,561 - 451 57,960 TB_STAT <15	HTS_SELF	Total	102,112	634,368	-	205,616	-	1,200	943,296
TB_STAT <15	PrEP_NEW	Total	5,882	36,300	-	10,239	-	451	52,872
TB_STAT 15+ 5,033 30,731 - 7,264 - - 43,028 TB_STAT Total 5,271 32,053 - 7,312 - - 44,636 TB_ART 15 57 347 - 1 - - 405 TB_ART 15+ 1,691 8,877 - 1,462 - - 12,030 TB_ART Total 1,748 9,224 - 1,463 - - 12,435 TB_PREV 15+ 45,182 230,120 - 5,831 - 84 38,154 TB_PREV 15+ 45,182 230,120 - 64,160 - 2,625 342,087 TB_PREV Total 48,926 258,615 - 69,991 - 2,709 380,241 TX_TB 15+ 204,950 1,070,826 - 289,098 - 26,219 1,591,093 TX_TB<	PrEP_CURR	Total	6,152	39,796		11,561	-	451	57,960
TB_STAT 15+ 5,033 30,731 - 7,264 - - 43,028 TB_STAT Total 5,271 32,053 - 7,312 - - 44,636 TB_ART 15 57 347 - 1 - - 405 TB_ART 15+ 1,691 8,877 - 1,462 - - 12,030 TB_ART Total 1,748 9,224 - 1,463 - - 12,435 TB_PREV 15+ 45,182 230,120 - 5,831 - 84 38,154 TB_PREV 15+ 45,182 230,120 - 64,160 - 2,625 342,087 TB_PREV Total 48,926 258,615 - 69,991 - 2,709 380,241 TX_TB 15+ 204,950 1,070,826 - 289,098 - 26,219 1,591,093 TX_TB<	TB STAT	<15	238	1,322	-	48	-	-	1,608
TB_STAT Total 5,271 32,053 - 7,312 - - 44,636 TB_ART <15					-		-	-	
TB_ART <15 57 347 - 1 - - 405 TB_ART 15+ 1,691 8,877 - 1,462 - - 12,030 TB_ART Total 1,748 9,224 - 1,463 - - 12,435 TB_PREV <15 3,744 28,495 - 5,831 - 84 38,154 TB_PREV 15+ 45,182 230,120 - 64,160 - 2,625 342,087 TB_PREV Total 48,926 258,615 - 69,991 - 2,709 380,241 TX_TB <15 12,225 81,778 - 19,755 - 803 114,561 TX_TB <15+ 204,950 1,070,826 - 289,098 - 26,219 1,591,093 TX_TB Total 217,175 1,152,604 - 308,853 - 27,022 1,705,654 GEND_GBV Total					-		-	-	
TB_ART 15+ 1,691 8,877 - 1,462 - - 12,030 TB_ART Total 1,748 9,224 - 1,463 - - 12,435 TB_PREV <15 3,744 28,495 - 5,831 - 84 38,154 TB_PREV 15+ 45,182 230,120 - 64,160 - 2,625 342,087 TB_PREV Total 48,926 258,615 - 69,991 - 2,709 380,241 TX_TB <15 12,225 81,778 - 19,755 - 803 114,561 TX_TB <15+ 204,950 1,070,826 - 289,098 - 26,219 1,591,093 TX_TB Total 217,175 1,152,604 - 308,853 - 27,022 1,705,654 GEND_GBV Total 12,791 93,404 - 34,377 - 1,160 141,732					-	•	-		-
TB_ART Total 1,748 9,224 - 1,463 - - 12,435 TB_PREV <15					-		-	-	
TB_PREV <15 3,744 28,495 - 5,831 - 84 38,154 TB_PREV 15+ 45,182 230,120 - 64,160 - 2,625 342,087 TB_PREV Total 48,926 258,615 - 69,991 - 2,709 380,241 TX_TB <15 12,225 81,778 - 19,755 - 803 114,561 TX_TB 15+ 204,950 1,070,826 - 289,098 - 26,219 1,591,093 TX_TB Total 217,175 1,152,604 - 308,853 - 27,022 1,705,654 GEND_GBV Total 12,791 93,404 - 34,377 - 1,160 141,732					-		-	-	
TB_PREV 15+ 45,182 230,120 - 64,160 - 2,625 342,087 TB_PREV Total 48,926 258,615 - 69,991 - 2,709 380,241 TX_TB <15 12,225 81,778 - 19,755 - 803 114,561 TX_TB 15+ 204,950 1,070,826 - 289,098 - 26,219 1,591,093 TX_TB Total 217,175 1,152,604 - 308,853 - 27,022 1,705,654 GEND_GBV Total 12,791 93,404 - 34,377 - 1,160 141,732		1			-		-	84	
TB_PREV Total 48,926 258,615 - 69,991 - 2,709 380,241 TX_TB <15	_				-		-		
TX_TB <15 12,225 81,778 - 19,755 - 803 114,561 TX_TB 15+ 204,950 1,070,826 - 289,098 - 26,219 1,591,093 TX_TB Total 217,175 1,152,604 - 308,853 - 27,022 1,705,654 GEND_GBV Total 12,791 93,404 - 34,377 - 1,160 141,732									
TX_TB 15+ 204,950 1,070,826 - 289,098 - 26,219 1,591,093 TX_TB Total 217,175 1,152,604 - 308,853 - 27,022 1,705,654 GEND_GBV Total 12,791 93,404 - 34,377 - 1,160 141,732		1							
TX_TB Total 217,175 1,152,604 - 308,853 - 27,022 1,705,654 GEND_GBV Total 12,791 93,404 - 34,377 - 1,160 141,732									
GEND_GBV Total 12,791 93,404 - 34,377 - 1,160 141,732							_		
	AGYW_PREV	Total	29,859	58,153		-		-	88,012

Partner Management and Stakeholder Engagement:

Agreements made during COP 2021 discussions, including those regarding national PrEP implementation, geographic focus, targets, budgets, SIMS, use of pipeline, partner implementation and partner management will be monitored and evaluated on a regular basis via both ad hoc check-ins and discussions as well as the joint HQ and country team POART discussions. It is expected that teams closely monitor partner performance and engage with each implementing partner on a regular basis to ensure achievement of targets, outcomes and impact in a manner consistent with the this memo, approved SDS, and budgets and targets as finalized in PEPFAR systems. Any partner with EITHER (1) <15 percent of target achievement at 3 months or (2) less than 40 percent of target achievement at 6 months must have a complete review of performance data (including trends in performance) and expenditures to date by program area, implement remediation, and conduct intensive follow-up.

In the HIV treatment program, most clients are continuing on treatment year after year and current on treatment (TX_CURR) performance should between 98 percent and 100 percent of the target. This can be adjusted in country context where HIV treatment services are still scaling up and the treatment new target is greater than 10 percent of treatment current. OVC programs are also similar in that there are clients continuing services from the previous year; if the IP is less than 80 percent of their target at Q2 performance review should be triggered.

For key populations programming, per MER Guidance and program requirements, HIV testing is a required element of the KP_PREV indicator. HIV testing services (HTS) or referring an individual to HTS is required to be offered (at least once during the reporting period and/or in accordance with WHO/national guidance) unless the individual had previously been tested positive for HIV. HIV prevention services must be tailored to individual risks. If the individual is self-identified as HIV positive, then HTS provision or referral to HTS will not be a required element of this indicator. Workplans for IPs should reflect these HTS requirements for key populations programming. Additionally, where referral to HTS is made, IP workplans and program design should incorporate measures to follow through on HTS with KP clients to ensure referral completion.

These elements (i.e. review, remediation, and follow-up) should be incorporated into the existing IP work plans. A second quarter of consistently poor performance by the IP should also result in implementation of a documented Performance Improvement Plan (PIP) or Correction Action Plan (CAP), in accordance with implementing agency policy. PIP indicators should reflect the core issue. If the issue is linkage of test positive to treatment the indicator measured should be test positive to new in treatment of greater than 85 percent. If the issue is retention it should be net new on treatment equal to 90 percent of new on treatment. After two quarters of intensive oversight and remediation for underperformance, partners should be close to full achievement of targets expected at quarter three. With a third quarter of consistently poor performance by the IP, implementing agencies should notify S/GAC the options the agency is implementing to address partner non-performance. including options for a shift to new partners. The country team should notify the S/GAC Chair and PPM immediately of the improvement plan.

Continued engagement with all stakeholders, including civil society and community members, multilateral partners and bilateral partners, is to continue throughout COP 2021 implementation. Core to this critical engagement is the sharing of and discussion surrounding quarterly results and achievement and findings from community-led monitoring. This continued engagement will ensure all parties' understanding of Tanzania's progress and help identify any strategic changes to be made in order to more efficiently and effectively reach epidemic control.